FTC Slams Amgen's Patent Arguments as 'Mockery of Section 2'

The Federal Trade Commission (FTC) has argued that Amgen's patent arguments in defense of its Enbrel arthritis drug are 'a mockery of Section 2.'

Amgen is seeking to fend off allegations that it cornered the market for Enbrel, a blockbuster medication used to treat rheumatoid arthritis and psoriasis.

The FTC maintains that acquisitions of patent applications should not receive blanket antitrust protections under the First Amendment. This stance has significant implications for how pharmaceutical companies navigate patent law in relation to their market dominance.